Daniel Asher Purchases 15,540 Shares of Ekso Bionics (NASDAQ:EKSO) Stock

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) major shareholder Daniel Asher purchased 15,540 shares of Ekso Bionics stock in a transaction that occurred on Thursday, February 19th. The stock was bought at an average cost of $12.30 per share, with a total value of $191,142.00. Following the completion of the transaction, the insider owned 270,432 shares of the company’s stock, valued at $3,326,313.60. The trade was a 6.10% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $11.18 on Friday. The stock’s 50-day moving average is $8.30 and its two-hundred day moving average is $5.77. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66. Ekso Bionics Holdings, Inc. has a 1 year low of $2.73 and a 1 year high of $13.27. The firm has a market cap of $29.29 million, a price-to-earnings ratio of -1.97 and a beta of 0.80.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ekso Bionics in a research note on Monday, December 22nd. Finally, HC Wainwright downgraded shares of Ekso Bionics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 31st. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Ekso Bionics presently has a consensus rating of “Hold” and an average price target of $10.50.

Institutional Investors Weigh In On Ekso Bionics

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Ekso Bionics in the 3rd quarter valued at $57,000. Shay Capital LLC purchased a new stake in shares of Ekso Bionics in the third quarter valued at about $67,000. Citadel Advisors LLC acquired a new stake in Ekso Bionics in the third quarter valued at about $198,000. Geode Capital Management LLC boosted its holdings in Ekso Bionics by 68.9% in the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after purchasing an additional 10,281 shares in the last quarter. Finally, Consolidated Portfolio Review Corp acquired a new position in Ekso Bionics during the 3rd quarter worth approximately $333,000. 6.42% of the stock is owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.